Binding of urokinase-type plasminogen activator (u-PA) to specific receptors (u-PAR) on the surface of endothelial cells contributes to the regulation of plasmin-dependent processes such as fibrinolysis and angiogenesis. We studied the efFect of raising intracellular levels of cyclic AMP (cAMP) and/or activating protein kinase C on the expression of u-PAR in cultured human umbilical vein endothelial cells (HUVEC). Incubation of HUVEC with forskolin stimulated a timeand concentration-dependent increase in the expression of u-PAR, measured both by an increase in the specific binding of radiolabeled single-chain u-PA (scu-PA) and by increased binding of anti-u-PAR antibodies. Maximal increase in u-PAR expression (81+11% above control, n =11) was not associated with a change in receptor affinity for scu-PA when HUVEC were incubated for 20 hours at 3TC with 50 jfM forskolin. Receptor induction by forskolin was inhibited when HUVEC were preincubated with deoxyadenosine monophosphate (DAM), an inhibitor of adenylyl cyclase. A similar increase in receptor expression (128±27% above control, n=3) was induced by the cAMP analogue 8-bromoadenosine 3':5'-cyclic monophosphate (50 mM). Forskolin induced an approximately twofold increase in the expression of a single~1.4-kb u-PAR messenger RNA (mRNA) transcript within 2 hours. Phorbol myristate acetate (PMA) also stimulated a timeand concentration-dependent increase in specific scu-PA binding. The maximal increase in u-PAR expression (254±27% above control, n=11) was observed when HUVEC were preincubated with 10 nM PMA for 20 hours. Induction of u-PAR by PMA was inhibited when HUVEC were preincubated with either cycloheximide or H7 but was unaffected by DAM. u-PAR induced by PMA showed a reduced affinity for scu-PA (Kd, 14±2 nM versus 3.6±0.6 nM, p<0.001; n=8). PMA stimulation for 20 hours resulted in a sixfold increase in a single :1.4-kb u-PAR mRNA transcript, with increased levels detectable within 30 minutes. Coincubation of HUVEC with optimal concentrations of forskolin and PMA for 20 hours produced a fully additive increase in u-PAR expression at both the mRNA and protein levels. These data suggest that both cAMP-dependent and protein kinase C-dependent protein kinase pathways may independently regulate u-PAR expression in human endothelial cells. (Circulation Research 1993;72.330-340) KEY WORDs * urokinase * endothelial cells * receptor E ndothelial cells in culture express receptors for urokinase-type plasminogen activator (u-PA) on their surfacel-3 that appear to be immunologically, structurally, and functionally similar to u-PA receptors (u-PAR) expressed on migratory cells such as From the Cardiovascular, Hematology/Oncology, and Rheuma-
macrophages, neutrophils, and tumor cells. [4] [5] [6] [7] [8] [9] Localization of u-PA activity to the endothelial cell surface may contribute to maintaining blood fluidity and accelerating other plasmin-dependent processes such as angio-genesis10 by 1) stimulating the conversion of the zymogen single-chain u-PA (scu-PA) to the enzymatically active form, 2) stimulating the activation of plasminogen, 3) protecting plasminogen activators from plasminogen activator inhibitors,3 or 4) directly increasing the intrinsic activity of scu-PA, perhaps by a conformational change induced by binding to u-PAR. Therefore, an increase in u-PAR expression may promote fibrinolysis and angiogenesis after vascular injury but may also contribute to pathological neovascularization in conditions such as diabetic retinopathy or tumor growth.
Most studies to date have focused on u-PAR regulation in migratory or tumor cells,11' 2 and relatively little is known about the regulation of u-PAR in endothelial cells. Miles and coworkers1 reported that human umbil-ical vein endothelial cells (HUVEC) in culture incubated with thrombin expressed 17% more binding sites for u-PA than unperturbed cells, but the mechanism by which this induction occurred and the effect of other agonists has not been described. The regulation of the u-PA gene by tumor promoters has been the subject of considerable study.13'14 Santell and Levin15 reported that agonists that activate protein kinase C and elevate the intracellular level of cyclic AMP (cAMP) act synergistically to stimulate the synthesis and release of tissuetype plasminogen activator by HUVEC, although the effect of these agonists on u-PA production and receptor expression was not addressed in this study. Since it is likely that plasminogen activators mediate their activity on the cell surface at least in part through their interaction with cell surface receptors, we analyzed the consequences of stimulating these two pathways for the expression of u-PAR in HUVEC.
Materials and Methods

Endothelial Cell Culture
Cultures of HUVEC were prepared and characterized by established methods described previously. 316 The cells were passaged two to four times in medium 199 (Gibco) supplemented with 10% heat-inactivated fetal calf serum (Flow Laboratories), penicillin/streptomycin (Gibco), and endothelial cell growth factor17 and grown to confluence on fibronectin-coated 24or 96well microtiter plates (Flow Laboratories). Cell counts were performed to ensure uniformity of cell numbers per well in control and treated cells. Cells were plated at 25,000 and 100,000 cells per well in the 96-and 24-well plates, respectively. In all experiments, the cells were stimulated in the complete medium noted above and growth factors were not withdrawn from either the control or treated cells.
Cell Stimulation
Confluent monolayers of HUVEC were incubated with phorbol myristate acetate (PMA, 10 nM, Sigma) or forskolin (50 ltM, Sigma) for various periods of time before the binding of scu-PA was measured. Concentration-dependence experiments were performed by incubating HUVEC with various concentrations of PMA or forskolin alone or in combination or with 8-bromoadenosine 3':Y5'-cyclic monophosphate (8- BrcAMP, Sigma) for 20 hours before binding of scu-PA was measured. In other experiments, HUVEC were preincubated for 2 hours with control medium, medium containing H7 (Seikagaku America Inc.), or deoxyadenosine monophosphate (DAM; 100 gM) before the addition of PMA (100 nM) to assess the effect of inhibiting protein kinase C and adenylyl cyclase, respectively. To determine whether protein synthesis was required for the induction of u-PAR, cycloheximide (1.0 or 2.5 ,ug/ml) was added to the medium alone or in the presence of PMA (10 nM) or forskolin (50 ,M), and binding of scu-PA was measured after an additional 20 hours of incubation. In some experiments, control or stimulated HUVEC were incubated with 0.1 unit/ml phosphatidylinositol-specific phospholipase C (PI-PLC; kindly provided by Dr. M. Low, New York) at 37°C for 1 hour before measurement of radioligand or antibody Urokinase-Type Plasminogen Activator Recombinant scu-PA was kindly provided by Dr. J. Henkin (Abbott Laboratories). Protein concentrations were determined with the Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Richmond, Calif.). Purified scu-PA was radiolabeled with 125I and lodo Beads (Pierce Chemical Co., Rockford, Ill.) as previously described3 to a specific activity of 1-6x 106 cpm/1Lg. Radiolabeled scu-PA was diluted in Dulbecco's phosphate-buffered saline (supplemented with calcium and magnesium, Gibco) containing 3 mg/ml bovine serum albumin (PBS-BSA) before use.
Radioligand Binding Studies
Monolayers of control or stimulated HUVEC were cooled to 4°C and washed three times with PBS-BSA buffer. '251-labeled scu-PA (3.6 nM unless otherwise noted) was then added for 2-3 hours to achieve equilibrium,3 and the cells were washed rapidly five times with PBS-BSA. The cells were removed with trypsin-EDTA (Gibco), and the cell-associated radioactivity was determined. Nonspecific binding was determined by measuring binding in the presence of a 50-100-fold molar excess of unlabeled scu-PA. Specific binding was determined by subtracting the amount nonspecifically bound from the total amount bound. The equilibrium dissociation constant (Kd) and maximum number of scu-PA binding sites per cell (Bmax) were determined by Scatchard analysis.18 In general, nonspecific binding represented <20% of the total binding. Approximately 6 fmol of scu-PA bound specifically per well in a 96-well plate,2 i.e., -1,000 cpm per well, at a specific activity of 3x 106 cpm/,ug. Differences between treated and untreated cells were assessed for statistical significance with a Student's t test; a value ofp<0.05 was considered significant. The Berenbaum model was used to test whether or not combinations of agonists caused a synergistic increase in u-PAR protein. The following formula was used to calculate the R value: R=(a/Ae)+(b/Be), where a is the concentration of agonist "a" in the combination, b is the concentration of agonist "b" in the combination, and A, is the equivalent concentration of agonist "a" that, when added alone, would give a result equal to the result obtained with the combination of agonists. In this model, an R value of <1 suggests synergy, a value of 1 suggests additivity, and a value >1 suggests inhibition. 19 As a test of the independence of the effects of forskolin and PMA on u-PAR protein expression, we used a two-factor analysis of variance (ANOVA), with a value ofp<0.05 considered significant.
Anti-u-PAR Antibodies
We developed polyclonal antiserum to a synthetic oligopeptide corresponding to amino acids 130-147 of the predicted sequence of the mature u-PAR recently cloned from a fibroblast complementary DNA (cDNA) library20 and identified in endothelial cells.3 The sequence of this oligopeptide has no significant homology with any other known protein (assessed by comparison with the NBRF database). The antiserum was produced in a BALB/c mouse immunized five times with 100 ,ug of the synthetic oligopeptide coupled to keyhole limpet hemocyanin. The specificity of the antiserum was demonstrated by Western blots of HUVEC extracts and by its binding.
Specific Bound (% of Control) 0 1 0 20 30 Time (hours) = p<.05 Forskolin vs Medium alone binding to HUVEC as described below. Western blotting was performed after sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions as previously described with a commercially available detection kit (Amersham, Arlington Heights, Ill.).3 In each experiment, binding of polyclonal murine anti-u-PAR antiserum and that of normal mouse serum were compared. Confirmatory experiments were performed with a monoclonal anti-u-PAR antibody (#3936, kind gift of R. Hart, American Diagnostica) that was raised against u-PAR from PMA-stimulated U-937 cells.
Measurement of u-PAR Expression by ELISA
As an independent method to quantify u-PAR protein antigen expression on intact HUVEC, we measured the binding of anti-u-PAR antibody to HUVEC using an enzyme-linked immunosorbent assay (ELISA). HUVEC were incubated with medium alone or medium containing forskolin (50 ,M) or PMA (10 nM) for 20 hours. After this incubation, cells were washed and treated with PI-PLC (0.1 unit/ml) in PBS or with PBS alone for 1 hour at 37°C. Monolayers of HUVEC were washed twice with PBS-BSA and then incubated with the primary polyclonal anti-u-PAR antiserum (1:100 dilution), control murine serum (1:100 dilution), or monoclonal anti-u-PAR (IgG2a,10 ,gg/ml) for 1 hour at 4°C. After three washes, the cells were incubated for 2 hours with peroxidaseconjugated antimurine immunoglobulin (Amersham) and washed five times. Substrate was added, and the absorbance at 492 nm (A492) was measured over time with a Dynatech Assay plate reader. Specific binding was defined as the difference in absorbance at 492 nm between HUVEC incubated with anti-u-PAR antiserum and control mouse serum. In most experiments, absorbance values for cells incubated with control mouse serum and cells incubated with buffer instead of primary antibody were the same. u-PAR expression was also measured in parallel wells on the same plate using radiolabeled scu-PA as described above.
RNA Isolation and Northern Blot Analysis
Total cytoplasmic RNA was isolated from HUVEC incubated for various times in medium alone or medium containing forskolin (50 ,uM), PMA (10 nM), or both.2' The RNA (20 ,ug) was separated by formaldehydeagarose gel electrophoresis and transferred to a Gene-Screen Plus membrane (Du Pont) by capillary action. The Northern blot was prehybridized in a formamide-Denhardt's solution in the presence of sonicated salmon sperm DNA (Sigma).3 Northern blot hybridization was performed with a full-length u-PAR probe cloned from PMA-stimulated U-937 cell cDNA using the polymerase chain reaction. 3 The cloned DNA insert (50 ng) was labeled by a nick translation kit (BRL). After an overnight hybridization, the blot was washed with 2x SSC solution (0.1% SDS) at room temperature and with 0.1x SSC solution (0.1% SDS) at 500C. The blot was then exposed to Kodak XAR film at -700C. Quantitative slot blot analysis was performed in a similar manner. u-PAR message was quantified by densitometric scanning of the autoradiograms and normalized for differences in loading using the messenger RNA (mRNA) level for glyceraldehyde-3-phosphate dehydrogenase (GAPD). The autoradiograms were exposed for various lengths of time to maximize the number of data points that fell in the linear range by densitometry.
Results
Forskolin Induces u-PAR Expression on HUVEC
HUVEC were incubated with forskolin, which has been shown previously to elevate cAMP levels in HUVEC,5 and the binding of radiolabeled scu-PA at equilibrium was determined ( Figure 1 ). Increased binding of scu-PA to HUVEC was first detected 8 hours after forskolin (50 ,M) was added to the medium, whereas no significant change in receptor expression was seen on cells incubated in control medium for up to 24 hours. The number of binding sites expressed by forskolin-treated HUVEC continued to increase over the next several hours, reaching a maximum between 10 and 20 hours after addition. Therefore, the latter time was chosen to perform concentrationdependence experiments (Figure 2A ). A detectable increase in scu-PA binding was observed when forskolin was added at final concentrations .1 ,uM. The maximum increase (81 +±11% above control, mean+tSEM, n=11) was achieved when HUVEC were incubated with 50 jiM forskolin. By Scatchard analysis, scu-PA bound to a single class of binding sites on forskolin-stimulated HUVEC (Bmax forskolin, 0.45±0.2 nM, n=4 versus control cells, 0.26±0.06 nM, n=8; p<005) having an affinity (K,, 3 .3±1.0 nM, n=4) comparable to that of unstimulated cells (Kd, 3.6-+-0.6 nM, n-8;p=NS).
The u-PAR expressed on several cell types has been found to be linked to the cell surface via a glycosylphosphatidylinositol (GPI) anchor. 22 The u-PAR can be released from the cell surface to varying extents by PI-PLC. 22 We tested whether the u-PAR expressed on control or forskolin-stimulated HUVEC were also sensitive to PI-PLC. By binding studies with radiolabeled scu-PA, pretreatment of HUVEC with PI-PLC resulted in a >90% reduction in specific binding.
As an independent method to quantify u-PAR protein expression, we measured the binding of a novel polyclonal anti-u-PAR antibody to control and forskolin-stimulated HUVEC with an ELISA. This antibody was generated by immunizing mice with a synthetic peptide corresponding to a unique sequence within the receptor (amino acids 130-147) predicted from the known cDNA sequence.20 The antibody recognized a single~-46-kd protein on Western blot analysis of proteins extracted from HUVEC ( Figure 3 ), and the protein recognized by this antibody on intact HUVEC was also susceptible to cleavage by PI-PLC ( Figure 4 ). When HUVEC were preincubated with 50 gM forskolin for 20 hours followed by anti-u-PAR antibody, the resultant A492 increased 39±17% above that for control cells (Figure 4 ), comparable to, although slightly less than, the increase in binding of radiolabeled scu-PA under the identical conditions. When forskolin-stimulated HUVEC were preincubated with PI-PLC, the binding of anti-u-PAR antibody was reduced to levels seen on control cells (Figure 4 ).
Mechanism of Induction of u-PAR by Forskolin
To test whether the induction of u-PAR by forskolin was due to an increase in cAMP, two approaches were used. First, preincubation of HUVEC with DAM (100 jiM), an inhibitor of adenylyl cyclase, inhibited the induction of u-PAR by forskolin by 70±40% (mean, n=3) but had no effect on receptor expression in unstimulated cells. Second, the cAMP analogue 8-BrcAMP induced a concentration-dependent increase in scu-PA binding (128±27% above control, n=3)( Figure 2B ), com-parable to that induced by forskolin ( Figure 2A ). These data support the hypothesis that increases in intracellular cAMP levels may cause an increase in u-PAR expression.
The time delay between the addition of forskolin and the induction of u-PAR suggested that protein synthesis for 1 hour at 40C, washed, and incubated with an enzyme-conjugated anti-murine secondary antibody. The relative amount of u-PAR per well was assessed after substrate addition by monitoring the absorbance at 492 nm (A492). Nonspecific antibody binding was assessed with normal mouse serum (diluted 1:100), and these values were subtractedfrom A492 obtained with the anti-u-PAR antiserum. In parallel wells, standard radioligand binding studies were performed with radiolabeled single-chain urokinase-type plasminogen activator (scu-PA) in the presence and absence of a 50-fold molar excess of unlabeled scu-PA. The specific binding in the presence and absence ofPIPLC ofboth antibody (n) and radioligand (m) are expressed as a percent ofthe respective control values. The data represent the mean of three experiments (+SEM). may be required. To test this hypothesis, HUVEC were incubated with cycloheximide, forskolin, or both for 24 hours at 37°C, and the binding of radiolabeled scu-PA was then compared with cells incubated in medium alone. HUVEC incubated with forskolin and no cycloheximide demonstrated the expected increase in binding to 188% of control, whereas scu-PA binding was reduced to 56% of control when the cells were stimulated with forskolin in the presence of cycloheximide (2.5 ,g/ml) ( Table 1 ). Of interest, addition of cycloheximide to unstimulated HUVEC reduced scu-PA binding to 40±5% of control, suggesting that protein synthesis is required to maintain u-PAR expression in cultured cells. Endothelial cells were coincubated for 24 hours with PMA (10 nM) or forskolin (50 ,^M) in the continual presence of cycloheximide (1 or 2.5 ,ug/ml). The cells were then assayed for specific binding of single-chain urokinase-type plasminogen activator. All results are expressed as a percentage of the specific binding expressed by cells incubated in complete medium alone. All data are expressed as the mean+SEM of three experiments.
Induction of u-PAR on HUVEC by PMA We next investigated whether stimulation of protein kinase C activity by PMA23 would also induce the expression of u-PAR on HUVEC. Preincubation of HUVEC with PMA (10 nM) led to an increase in scu-PA binding after an initial delay of approximately 6 hours ( Figure 5 ). The maximum increase in scu-PA binding was detected after 24 hours of incubation. The number of u-PAR per cell declined over the next 28 hours but remained above control. This finding is consistent with the known downregulation of protein kinase C activity after prolonged stimulation by PMA.24 When 10 nM PMA was added, specific binding of radiolabeled scu-PA (3.6 nM) increased 254±27% above control (n=11) ( Figure 6 ). When the binding data were evaluated by Scatchard analysis (Figure 7) , HUVEC stimulated with PMA appeared to express approximately a threefold increase in the maximum number of binding sites (B,, 0.67±0.26 versus 0.26±0.06 nM for control, p<0.05; n=7) associated with a significant increase in the apparent Kd of scu-PA for the receptor compared with unstimulated cells (Kd, 14±2 nM versus 3.6±0.6 nM, p<0.001; n=8). These data would suggest that PMA induces an increased number of u-PAR having lower affinity, although these data do not exclude the presence of two different u-PAR.
We then performed a series of experiments in an attempt to identify the mechanism by which this decrease in affinity was produced. We reasoned that the change in affinity could result from 1) an alteration in the processing of the u-PAR (e.g., induction of a transmembrane form of the receptor, modification of the PI anchor, or changes in the extent or sites of glycosylation), 2) the induction of a different u-PAR protein, or 3) an interaction between u-PAR (e.g., dimerization) on the cell surface.
We first assessed whether the u-PAR expressed by PMA-treated cells were still sensitive to PI-PLC. Of the scu-PA binding sites on PMA-stimulated and unstimulated HUVEC, >90% were removed from the cell surface after incubation with the enzyme. These results were confirmed by ELISA using the anti-u-PAR antibody (Figure 4 ), in that binding of the anti-u-PAR antibody also increased. The binding of both antibody and radioligand could be prevented to a large extent by pretreating the cells with PI-PLC. This result suggests that essentially all the u-PA binding sites on PMAstimulated HUVEC remain attached to the cell surface through a GPI linkage. Because u-PAR detection by ELISA using a polyclonal antibody appeared less sensitive than the radioligand binding assay, we repeated these studies with a monoclonal antibody raised against u-PAR harvested from PMA-stimulated U-937 cells with PI-PLC (R. Hart, personal communication). Using the same method of data analysis as in Figure 4 increase in specific antibody binding, whereas forskolin treatment resulted in a twofold increase. Parallel radioligand binding data performed in one of these experiments was in nearly complete agreement (PMA, 5.9-fold increase; forskolin, 2.1-fold increase), confirming the extent of increased antigen expression by both agonists.
We next used Western blotting to determine whether PMA induced a change in the molecular mass of the predominant u-PAR species found on the surface of HUVEC. 3 The monoclonal antibody used in the ELISA did not react at all with endothelial cell extracts by Western blotting after SDS-PAGE under reducing conditions. However, the polyclonal anti-u-PAR antibody raised against the oligopeptide reacted predominantly with a single~:z46-kd band in both control (Figure 3 , lane 2) and PMA-treated cells (lane 1), with an increase in the size (i.e., area of staining) and intensity of this band in PMA-treated cells (10 nM, 24 hour), supporting the notion that an increase in a very similar u-PAR protein antigen was induced. Control murine serum showed no binding in this region (not shown).
Finally, we examined whether the reduction in binding affinity could be attributed to the increased number of receptors expressed on PMA-stimulated cells, a situation that might favor interactions of u-PAR with other receptors or nonreceptor proteins with a concomitant loss in binding efficiency. To address this possibility, HUVEC were incubated with the concentration of PMA (10 nM) that produced the maximum number of receptors. However, the incubation was terminated at a time when fewer receptors would be expressed. Binding of scu-PA to HUVEC stimulated with PMA for 6 hours was compared with HUVEC stimulated with 50 gM forskolin for 20 hours. Under these conditions, PMAstimulated cells and forskolin-stimulated cells expressed comparable number of receptors, and the dissociation constants estimated from the Scatchard analyses were essentially the same as well (Figure 8 ). These data support but do not unequivocally prove the notion that the change in receptor affinity may be influenced by receptor density.
Mechanism of Induction of u-PAR by PMA
Several experiments were performed to determine the mechanism by which PMA induces u-PAR. First, a requirement for protein synthesis was examined using HUVEC coincubated with PMA (10 nM) and cycloheximide (2.5 gg/ml). Cycloheximide inhibited the expression of u-PAR on PMA-stimulated HUVEC to levels below those expressed by unstimulated cells, although the inhibition was incomplete (Table 1) . Second, HUVEC were preincubated with either 10 ,uM H7, an inhibitor of protein kinase C, or 100 AtM DAM, an inhibitor of adenylyl cyclase, before PMA was added. H7 decreased binding of radiolabeled scu-PA to PMA-stimulated cells by 35% (p<0.05 compared with cells treated with PMA alone), whereas DAM had no effect. Third, prolonged stimulation of HUVEC with PMA, which has been reported to decrease protein kinase C activity, was associated with a decrease in u-PAR expression ( Figure 5) .
Bound (nM) FIGURE 8. Scatterplot showing induction of urokinase-type plasminogen activator receptors by phorbol myristate acetate (PMA) and forskolin: Scatchard analysis of the effect of decreased time of PMA stimulation. Human umbilical vein endothelial cells (HUVEC) were incubated with medium alone (a), 50 ,uMforskolin for 20 hours (rz), or 10 nM PMA (a) for 6 hours. The cells were cooled to 4°C, and the specific binding of 125I single-chain urokinase-type plasminogen activator (scu-PA) was determined at equilibrium. Binding of scu-PA to HUVEC incubated in medium alone for 4 or 20 hours was essentially identical.
Costimulation of u-PAR Expression by PMA and Forskolin
Costimulation experiments were then performed as a means of determining whether PMA induced u-PAR through a mechanism dependent on cAMP or whether the two pathways independently regulated u-PAR expression. HUVEC were stimulated with optimal or suboptimal concentrations of PMA and either forskolin or 8-BrcAMP. At most concentrations tested, expression of u-PAR by HUVEC costimulated with PMA and forskolin equaled or exceeded the arithmetic sum of the effects seen with either agonist alone (Figure 9 ). For example, when both agonists were added to the medium at their maximal effective concentrations, u-PAR expression was increased 575% above control values, compared with increases of 80% and 350% above control values (arithmetic sum, 430%) induced by forskolin and PMA, respectively, when added separately (mean of three experiments). Similarly, when HUVEC were stimulated with maximal effective concentrations of PMA, 8-BrcAMP, or both, u-PAR expression increased 128%, 97%, and 245% above control, respectively (mean, n=2), suggesting that PMA does not mediate its effect by stimulating adenylyl cyclase activity and that the effects are additive irrespective of adenylyl cyclase activity. With the Berenbaum model, the results obtained when HUVEC were stimulated with 1 nM PMA and 1 ,uM forskolin produce an R value of 0.7, consistent with a mild degree of synergy. We also analyzed all of the data from the three separate costimulation experiments (Figure 9 ) using a two-factor ANOVA. For forskolin (F= 15.9) or for PMA (F= 176) considered alone, the drug effect was highly significant (p<0.0001 in each case). The independence of each effect was demonstrated by the lack of a significant interaction as determined by the ANOVA interaction term (F=0.793,p=0.63). Therefore, at the protein level, forskolin and PMA appear to induce fully additive but not synergistic increases in u-PAR. Finally, we tested the effect of stimulation of each pathway alone or together on the steady-state levels of u-PAR mRNA by Northern blot analysis. HUVEC incubated with PMA and forskolin together expressed higher steady-state u-PAR mRNA levels than cells stimulated with either agent alone. This additive effect was detected as early as 30 minutes, at which time cells stimulated with PMA or forskolin expressed 1.6-fold and 1.9-fold more u-PAR mRNA, respectively, whereas HUVEC stimulated with both agonists expressed 3.7-fold more u-PAR mRNA than control cells (not shown).
A somewhat more than additive increase in u-PAR mRNA level was detected at 20 hours. Forskolin alone led to a 1.6-fold increase in steady-state mRNA levels ( Figure 10 Regulation of these receptors on endothelial cells may be required for the orderly progression of vascular repair and angiogenesis. Although knowledge is increasing about the regulation of plasminogen activator'3'4 and inhibitor production by endothelial cells,26 relatively little is known about the mechanisms by which their cellular receptors are regulated.
Our studies indicate that elevation of intracellular cAMP levels in HUVEC leads to a modest increase in the number of u-PAR expressed on the cell surface. Induction of these receptors requires protein synthesis and was preceded by an increase in the specific mRNA message. These findings make it unlikely that the increased expression involves solely a translocation of preformed receptors from a cytoplasmic pool, although a contribution from such a mechanism has not been excluded. The receptors induced by forskolin showed an affinity for scu-PA similar to those expressed on unstimulated HUVEC, and essentially all were linked to the cell surface by a GPI anchor cleavable by PI-PLC.22 This latter result suggests either that the enzymes and precursors involved in processing the nascent protein at the carboxy terminus and forming the GPI anchor are already present in excess or that they are induced to a similar extent by an increase in intracellular cAMP.
We also found that PMA induced more than a threefold increase in the expression of u-PAR on HUVEC, a far more modest effect than that observed on U-937 cells.27 However, in all experiments, the HUVEC were grown in the presence of 10% fetal calf serum and endothelial cell growth factor (predominantly acidic fibroblast growth factor), which may have raised baseline u-PAR levels compared with unstimulated cells. In a separate series of experiments (Z. Kluger et al, manuscript submitted for publication), we have demonstrated that both acidic and basic fibroblast growth factors do increase u-PAR levels in HUVEC, a finding consistent with the studies of Mignatti and coworkers,28 who demonstrated increased u-PAR expression in bovine capillary endothelial cells and HUVEC by basic fibroblast growth factor. These data suggest that the stimulation with either forskolin or PMA might have been more dramatic if the control endothelial cells had been growth factor deprived.
Induction of u-PAR by PMA also required protein synthesis but was only partially inhibited by H7, suggesting an effect mediated by intracellular pathways in addition to activation of protein kinase C. Therefore, we investigated whether the induction of u-PAR by PMA (i.e., protein kinase C) involved an activation of adenylyl cyclase. Phorbol esters have been reported to enhance adenylyl cyclase activity by covalent modification of the catalytic unit in some cell types,2429,30 although PMA alone has been reported to decrease cAMP levels in HUVEC."5 Several pieces of evidence suggest that the induction of u-PAR by PMA was not mediated through an effect on cAMP. First, DAM, at concentrations that inhibited the induction of u-PAR by forskolin, did not inhibit the induction of u-PAR by PMA. Second, when HUVEC were costimulated with maximally effective or submaximal concentrations of PMA and forskolin or PMA and 8-BrcAMP, an additive or mildly synergistic increase in receptor expression was observed. Finally, a formal two-way ANOVA of costimulation data in a four-by-four design with three doses of each drug including a maximal dose for each drug demonstrated a highly significant effect for each drug with a very low F test score for the interaction between the two drugs. Taken together, these results suggest that PMA and agonists that elevate intracellular levels of cAMP stimulate the expression of u-PAR through independent pathways.
The increase in receptor number induced by PMA was accompanied by a reduction in its apparent affinity for scu-PA, whereas the affinity of the forskolin-stimulated receptor remained unchanged. The mechanism by which receptor affinity is modulated is unclear but could result either from a change in the behavior of the receptor expressed on unstimulated cells or by induction of a second binding site not expressed, or poorly expressed, on unstimulated HUVEC. To distinguish between these possibilities, we performed three sets of experiments.
First, u-PAR on PMA-stimulated U-937 cells has recently been shown to be linked to the cell surface through a GPI anchor.22 It is not known whether the receptors on HUVEC are anchored in a similar manner or whether a portion of the receptors are expressed as transmembrane proteins. In addition, PMA might modify the fatty acids or other components of the anchor itself in such a way as to affect receptor function, changes that might be reflected in an altered susceptibility to cleavage by PI-PLC.3' Our data indicate that u-PAR on HUVEC are linked in a similar manner, although the endothelial cell receptor is more sensitive to cleavage by PI-PLC (>90%) than is the receptor on U-937 cells (-50-60%) (unpublished observation). 22 Whether this difference results from variation in the accessibility of u-PAR to the enzyme, binding to other proteins, or differences in posttranslational modification of the GPI anchor among the cell types3' remains to be determined. We observed no change in the susceptibility of the u-PAR induced by PMA (or forskolin) to cleavage by PI-PLC, again indicating that it is unlikely that a transmembrane form of the receptor was induced.
Second, we measured u-PAR antigen by use of a polyclonal antibody developed against a unique peptide sequence present in the middle of the mature protein. This antibody recognizes a single =46-kd protein in unstimulated HUVEC (Figure 3 ) and PMA-stimulated U-937 cells (data not shown). When HUVEC were stimulated with forskolin or PMA, antibody binding increased, supporting the hypothesis that the receptor induced by each agonist was antigenically similar if not identical to the protein expressed by unstimulated cells. This interpretation gained additional support from the Western blot experiments, which showed an increase in a single -46-kd protein in extracts from PMA-stimulated HUVEC. Moreover, antibody binding was reduced to a comparable extent on unstimulated and PMA-stimulated HUVEC by PI-PLC ( Figure 4 ). The observation that binding of the polyclonal anti-u-PAR antibody to PMA-stimulated cells did not increase to the same extent as did the binding of radiolabeled scu-PA probably reflects the lower affinity of the antibody for the receptor and differences in the sensitivitity of the two assays as performed. However, using a monoclonal antibody (No. 3936) raised against u-PAR from PMA-stimulated U-937 cells, we observed an increase in u-PAR antigen expression with PMA similar to that detected by radioligand binding assays.
Third, we hypothesized that if the change in affinity were simply a result of receptor density, then stimulation of cells with PMA sufficient to induce the same number of binding sites as forskolin would produce u-PAR having similar affinity. This is in fact what we observed (Figure 8) . A similar inverse relation between receptor number and affinity was observed during the differentiation of human monocytes in culture.32 Formation of intramolecular or intermolecular complexes with reduced affinity for scu-PA might be favored by a higher receptor density. The number and composition of such complexes may vary among cell types. However, other groups have reported that interferon-y increases u-PAR on U-937 cells without a concomitant decrease in affinity.12 '33 We speculate that in endothelial cells, high receptor density may favor homodimer, homotetramer, or heterodimer formation, as suggested by higher-molecular-mass bands isolated from endothelial cell extracts by scu-PA-sepharose affinity chromatography,3 and that these forms may bind scu-PA with lower affinity. We have not excluded the possibility that the shorter incubation with PMIA did not allow time for the specific posttranslation modifications (e.g., altered glycosylation patterns) that actually reduce receptor affinity.
Finally, we performed Northern blot analyses using a full-length cDNA probe for the u-PAR that recognizes a single transcript in both unstimulated HUVEC and PMA-stimulated U-937 cells3 to determine whether a second species of mRNA or alternative splicing of the message could be detected after stimulation of HUVEC with PMA, forskolin, or both. Only a single 41.4-kb transcript was detected on Northern blot analysis of RNA extracted from HUVEC stimulated with forskolin, PMA, or both.
In summary, our studies demonstrate a fully additive but probably not synergistic effect of forskolin and PMA on u-PAR protein expression. There was, however, a suggestion of synergy at the steady-state mRNA level. The reason for this discordance is not clear but could hypothetically be related to several factors, including 1) more rapid turnover of u-PAR protein (e.g., during more rapid or extensive internalization by u-PA/PAI-1 complexes); 2) more basal localization of u-PAR, which might not be available for binding to radiolabeled scu-PA; or 3) limiting amounts of GPI anchor. The mechanism of the synergy is also unknown at the present time and could involve effects on transcription as well as on message stability. What appears clear, however, is that stimulation of either the protein kinase C-dependent or cAMP-dependent protein kinase pathways can independently modulate u-PAR expression in human endothelial cells in culture. Whether activation of these pathways in vivo also modulates u-PAR expression remains to be determined.
